Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Simcere Pharmaceutical Group Limited
  6. Summary
    2096   HK0000658531

SIMCERE PHARMACEUTICAL GROUP LIMITED

(2096)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
10.44 9 9.45 10.64 9.76 Last
8530000 12119000 6631088 8930401 9141401 Volume
-6.28% -13.79% +5.00% +12.59% -8.27% Change
Estimated financial data (e) (USD)
Sales 2021 986 M - -
Net income 2021 177 M - -
Net Debt 2021 229 M - -
P/E ratio 2021 19,4x
Yield 2021 -
Sales 2022 1 232 M - -
Net income 2022 229 M - -
Net Debt 2022 115 M - -
P/E ratio 2022 14,8x
Yield 2022 -
Capitalization 3 290 M 3 290 M -
EV / Sales 2021 3,57x
EV / Sales 2022 2,76x
Nbr of Employees 6 512
Free-Float 13,6%
More Financials
Company
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of Simcere Pharmaceutical Group Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SIMCERE PHARMACEUTICAL GROUP LIMITED
07/30Simcere Pharmaceutical Group Limited Announces Announcement in Relation to th..
CI
06/30Simcere Pharmaceutical Group Limited Announces Resignation of Feng Jie as Joi..
CI
06/29VIVORYON THERAPEUTICS N : Licenses Alzheimer's Disease Drugs to China's Simcere ..
MT
06/28SIMCERE PHARMACEUTICAL : Secures License to Develop, Commercialize Vivoryon Ther..
MT
06/28PRESS RELEASE : Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Updat..
DJ
06/28PRESS RELEASE : Vivoryon Therapeutics and Simcere Announce Strategic Regional Li..
DJ
06/25Simcere Pharmaceutical Group Limited Declares Final Dividend for the Year End..
CI
06/17SIMCERE PHARMACEUTICAL : Cancer Treatment Approved for Clinical Study
MT
06/17Simcere Pharmaceutical Group Limited Announces Approval on Clinical Trial App..
CI
06/15SIMCERE PHARMACEUTICAL : Pharma Bags Clinical Trial Approval in China for New Us..
MT
05/25Simcere Pharmaceutical Group Limited Recommends Final Dividend for the Year E..
CI
04/28SIMCERE PHARMACEUTICAL : Further announcement profit forecast in relation to dis..
PU
04/26Certain Ordinary Shares of Simcere Pharmaceutical Group Limited are subject t..
CI
04/19SIMCERE PHARMACEUTICAL : Nomura Starts Simcere Pharmaceutical Group at Buy With ..
MT
04/19PRESS RELEASE : Evotec enters partnership with Kazia Therapeutics for clinical d..
DJ
More news
News in other languages on SIMCERE PHARMACEUTICAL GROUP LIMITED
06/29Vivoryon kan langer door met kaspositie
04/19DGAP-NEWS : Evotec und Kazia Therapeutics gehen Partnerschaft zur klinischen Ent..
More news
Analyst Recommendations on SIMCERE PHARMACEUTICAL GROUP LIMITED
More recommendations
Chart SIMCERE PHARMACEUTICAL GROUP LIMITED
Duration : Period :
Simcere Pharmaceutical Group Limited Technical Analysis Chart | 2096 | HK0000658531 | MarketScreener
Technical analysis trends SIMCERE PHARMACEUTICAL GROUP LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 8,11 CNY
Average target price 10,76 CNY
Spread / Average Target 32,6%
EPS Revisions
Managers and Directors
Jin Sheng Ren Chairman & Chief Executive Officer
Yu Shan Wan Chief Financial Officer & Executive Director
Pin Wang Chief Scientific Officer
Rui Lin Song Independent Non-Executive Directors
Jian Guo Wang Independent Non-Executive Director